EUVIMEDEUVIMED entdecken
Open Access

Enhancing prognostication and treatment response evaluation in primary CNS lymphoma with 18F-FDG-PET/CT

Minyoung Oh iD, Hyungwoo Cho, Ji Eun Park, Ho Sung Kim, Heounjeong Go, Chan-Sik Park, Sang-Wook Lee, Sang Woo Song, Young-Hoon Kim iD, Young Hyun Cho, Seok Ho Hong, Jeong Hoon Kim und 4 weitere

Neuro-Oncology · 2024

DOI: 10.1093/neuonc/noae146 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2024. Verfasst von Minyoung Oh und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography, Central Nervous System Neoplasms, Radiopharmaceuticals. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Asan Institute for Life Sciences, Korean Health Industry Development Institute, Ministry of Health & Welfare, Republic of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) in the prognostication and response evaluation of primary central nervous system lymphoma (PCNSL) remains inadequately defined.

Methods

We conducted a retrospective analysis of 268 consecutive newly diagnosed patients with PCNSL between 2006 and 2020. Of these patients, 105 and 110 patients were included to evaluate the prognostic value of baseline and post-treatment 18F-FDG-PET/CT scans, respectively. Tumor uptake was considered positive when it exceeded that of the contralateral brain upon visual assessment. Quantitative analysis of baseline 18F-FDG-PET/CT included measurement of the maximal standardized uptake value (SUVmax), total metabolic tumor volume (TMTV), and total lesion glycolysis (TLG).

Results

The median age of the 268 patients was 62 years (range: 17–85), with 55% being male. The median progression-free survival (PFS) was 24.5 months (95% CI: 19.9–29.1), and the median overall survival (OS) was 34.5 months (95% CI: 22.9–46.1). The average SUVmax was 15.3 ± 5.7 and the mean TMTV and TLG were 12.6 ± 13.9 cm3 and 135.0 ± 152.7 g, respectively. Patients with a baseline TMTV ≥ 17.0 cm3 had significantly shorter OS (12.5 vs 74.0 months, P = .011). Post-treatment metabolic response by 18F-FDG-PET/CT significantly predicted PFS (median: 10.5 vs 46.0 months, P = .001) and OS (median: 21.0 vs 62.0 months, P = .002), whereas anatomic response by contrast-enhanced MRI showed no statistically significant differences in PFS (P = .130) or OS (P = .540).

Conclusion

Baseline TMTV and post-treatment metabolic response, as assessed by 18F-FDG-PET/CT, are significant prognostic factors in patients with PCNSL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorodeoxyglucose F18Positron Emission Tomography Computed TomographyCentral Nervous System NeoplasmsRadiopharmaceuticalsLymphomaHumansMaleFemaleMiddle AgedAgedAdultRetrospective StudiesPrognosisAged, 80 and overYoung AdultAdolescentSurvival RateFollow-Up Studies

Stichwörter der Autor:innen

PCNSLPETTLGTMTVprognosis

Substanzen

Fluorodeoxyglucose F18Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Department of Neurological Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

ORCID-Profile: Minyoung Oh, Young-Hoon Kim

Förderung

  • Asan Institute for Life Sciences
  • Korean Health Industry Development Institute
  • Ministry of Health & Welfare, Republic of Korea

Zitieren

APA

Oh, M., Cho, H., Park, J. E., Kim, H. S., Go, H., Park, C. S., Lee, S. W., Song, S. W., Kim, Y. H., Cho, Y. H., Hong, S. H., Kim, J. H., Lee, D. Y., Ryu, J. S., Yoon, D. H., & Kim, J. S. (2024). Enhancing prognostication and treatment response evaluation in primary CNS lymphoma with 18F-FDG-PET/CT. Neuro-Oncology. https://doi.org/10.1093/neuonc/noae146

Vancouver

Oh M, Cho H, Park JE, Kim HS, Go H, Park CS, et al. Enhancing prognostication and treatment response evaluation in primary CNS lymphoma with 18F-FDG-PET/CT. Neuro-Oncology. 2024. doi:10.1093/neuonc/noae146

BibTeX
@article{Oh2024,
  author = {Oh, Minyoung and Cho, Hyungwoo and Park, Ji Eun and Kim, Ho Sung and Go, Heounjeong and Park, Chan-Sik and Lee, Sang-Wook and Song, Sang Woo and Kim, Young-Hoon and Cho, Young Hyun and Hong, Seok Ho and Kim, Jeong Hoon and Lee, Dong Yun and Ryu, Jin-Sook and Yoon, Dok Hyun and Kim, Jae Seung},
  title = {Enhancing prognostication and treatment response evaluation in primary CNS lymphoma with 18F-FDG-PET/CT},
  journal = {Neuro-Oncology},
  year = {2024},
  doi = {10.1093/neuonc/noae146}
}
Kostenlos starten →